LPCN - Lipocine Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Lipocine Inc.

675 Arapeen Drive
Suite 202
Salt Lake City, UT 84108
United States

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Dr. Mahesh V. PatelCo-Founder, Chairman, Pres & CEO572.25kN/A1957
Mr. Morgan R. Brown CPA, MBAExec. VP, CFO & Corp. Sec.404.25kN/A1968
Logan MorseVP of Sales, Marketing & OperationsN/AN/A1970
Dr. William I. Higuchi Ph.D.Chief Scientific ConsultantN/AN/A1931
Dr. Anthony DelConteChief Medical DirectorN/AN/A1958
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase II testing; LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase I Clinical trial for the treatment of non-alcoholic steatohepatitis. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Corporate Governance

Lipocine Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.